© Springer International Publishing AG 2018Adam S. Cheifetz and Joseph D. Feuerstein (eds.)Treatment of Inflammatory Bowel Disease with Biologics https://doi.org/10.1007/978-3-319-60276-9_11 11. Biologic Therapy in Pediatric Inflammatory Bowel Disease Sonal Patel1 and Jennifer Strople1 (1) Division of Pediatric…
Authors Number of participants (n) Study design Relapse rate Significant predictors of relapse Predictors evaluated but not found to be significant Recapture rate CD Brooks et al. [52] 86…
Study Infliximab (n) Non-infliximab (n) Total (n) Odds ratio Appau et al. [8] 60 329 389 2.93 (1.63–5.27) Canedo et al. [11] 65 160 225 1.19 (0.58–2.42) Kasparek et al….
Fig. 3.1 Induction of remission with corresponding placebo rates from seminal clinical trials for each anti-TNF (note: trials had different inclusion criteria and end points and thus while presented on…
Infliximab Adalimumab Certolizumab Golimumab CT-P13 ABP501 sTNF binding Y Y Y Y Y Y mTNF binding Y Y Y Y Y Y mTNF reverse signaling Y Y ? Y…
© Springer International Publishing AG 2018Adam S. Cheifetz and Joseph D. Feuerstein (eds.)Treatment of Inflammatory Bowel Disease with Biologics https://doi.org/10.1007/978-3-319-60276-9_4 4. Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease David I. Fudman1 and Sarah N. Flier1 …
Term Definition Adverse pregnanc y outcomes Spontaneous abortion/miscarriage Induced abortion Preterm birth (delivery <37 weeks of gestation) Small for gestational age (birth weight <10th percentile for gestational age) Stillbirth Ectopic…
Anti-TNFα medication Authors, date Study summary Study population, sample size Dosing information Clinical response Clinical remission and mucosal improvement Infli ximab Rutgeerts et al. [15] Induction (ACT 1) 364 TNF-naïve…
